- Home
- ICON vs XRTX Comparison
ICON vs XRTX Comparison
Compare ICON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- XRTX
- Stock Information
- Founded
- ICON 2023
- XRTX 2011
- Country
- ICON Greece
- XRTX Canada
- Employees
- ICON N/A
- XRTX N/A
- Industry
- ICON
- XRTX Pharmaceuticals and Biotechnology
- Sector
- ICON
- XRTX Health Care
- Exchange
- ICON Nasdaq
- XRTX Nasdaq
- Market Cap
- ICON 4.5M
- XRTX 4.1M
- IPO Year
- ICON 2024
- XRTX N/A
- Fundamental
- Price
- ICON $2.31
- XRTX $1.79
- Analyst Decision
- ICON Strong Buy
- XRTX Strong Buy
- Analyst Count
- ICON 1
- XRTX 1
- Target Price
- ICON $7.00
- XRTX $14.00
- AVG Volume (30 Days)
- ICON 32.1K
- XRTX 8.9M
- Earning Date
- ICON 09-24-2024
- XRTX 08-14-2024
- Dividend Yield
- ICON 3.35%
- XRTX N/A
- EPS Growth
- ICON N/A
- XRTX N/A
- EPS
- ICON 6.89
- XRTX N/A
- Revenue
- ICON $4,886,000.00
- XRTX N/A
- Revenue This Year
- ICON N/A
- XRTX N/A
- Revenue Next Year
- ICON N/A
- XRTX N/A
- P/E Ratio
- ICON $0.35
- XRTX N/A
- Revenue Growth
- ICON N/A
- XRTX N/A
- 52 Week Low
- ICON $2.03
- XRTX $1.09
- 52 Week High
- ICON $3.85
- XRTX $67.72
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- XRTX 48.73
- Support Level
- ICON N/A
- XRTX $1.60
- Resistance Level
- ICON N/A
- XRTX $2.08
- Average True Range (ATR)
- ICON 0.00
- XRTX 0.41
- MACD
- ICON 0.00
- XRTX -0.02
- Stochastic Oscillator
- ICON 0.00
- XRTX 34.39
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.